Company profile: SensID
1.1 - Company Overview
Company description
- Provider of reference materials for DNA diagnostic procedures, designed for R&D, validation, external control, accreditation preparation, round robin tests, and integration into diagnostic devices or kits. Offerings include cfDNA multiplex sets for liquid biopsy (AKT1, BRAF, ERBB2, KRAS, PIK3CA; EGFR for NSCLC) and FFPE reference standards (PIK3CA variants, MSI).
Products and services
- EGFR-Multiplex Set cfDNA: A clinical-grade cfDNA-based reference material engineered for liquid biopsy assays, enabling diagnostics and validation of EGFR diagnostic kits for Non-Small Cell Lung Cancer with relevant mutation targets
- 5-Gene-Multiplex Set cfDNA: A custom-engineered reference material for liquid biopsy assays, used for diagnostics and validation of diagnostic kits, featuring mutations in AKT1, BRAF, ERBB2, KRAS, and PIK3CA
- Idyllaâ„¢ MSI FFPE Reference Set: A laboratory-grade FFPE reference set constructed for microsatellite instability testing in clinical genomics workflows, in formalin-fixed, paraffin-embedded format supporting MSI assay workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SensID
Denali Therapeutics
HQ: United States
Website
- Description: Provider of investigational therapeutics focused on neurodegenerative diseases, including BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease, DNL343 for ALS, SAR443820/DNL788 (RIPK1-targeting) for multiple sclerosis, and TAK-594/DNL593 (PTV:PGRN) for frontotemporal dementia–granulin, as well as DNL310 (ETV:IDS) for Hunter syndrome and DNL126 (ETV:SGSH) for MPS IIIA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Denali Therapeutics company profile →
Presidio Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics for viral infections, including HCV and HIV, discovering, developing, and commercializing treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Presidio Pharmaceuticals company profile →
Color Health
HQ: United States
Website
- Description: Provider of a healthcare delivery platform offering clinical-grade genetic testing for cancer and heart risk, cancer care management, cardiometabolic care, and COVID-19 testing, vaccination, and treatment with telehealth and prescription delivery, plus a research platform with genetic sequencing, bioinformatics, and participant engagement for large-scale health initiatives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Color Health company profile →
NEO New Oncology
HQ: Germany
Website
- Description: Provider of the NEO diagnostic platform, designed and developed by NEO New Oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NEO New Oncology company profile →
Focus Diagnostics
HQ: United States
Website
- Description: Provider of molecular and immunodiagnostic products and platforms for hospitals and commercial laboratories worldwide. Offers Simplexa molecular chemistries, HerpeSelect type-specific serology, and DxSelect IFA/ELISA kits for diseases such as West Nile Virus and Rickettsia, plus Luminex LTG, LIAISON PLEX multiplexing (including Respiratory Flex Assay), and LIAISON XL/XS automated CLIA assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Focus Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SensID
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SensID
2.2 - Growth funds investing in similar companies to SensID
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SensID
4.2 - Public trading comparable groups for SensID
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →